Tag Archives: TIX100

FDA Releases Status on GLP-1RA Supply; AZ Initiates Baxdrostat/Dapa Trial in CKD and CV; TIXiMED Announces $2.65M Investment

Three cardiometabolic-related news items have been observed: FDA clarified the tirzepatide shortage resolution and impact on compounding pharmacies (view report); AstraZeneca initiated a Ph3 baxdrostat/dapagliflozin renal outcomes and CV mortality trial (view CT.gov record); and TIXiMED announced a $2.65M Helmsley Charitable Trust investment (view press release). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

FENIX Interview with TIXiMED – Oral T1DM Therapeutic Developer

FENIX sat down with Anath Shalev, founder of TIXiMED and licensed endocrinologist, and Stephen Daly, CFO of TIXiMED, for an in-depth interview on the company’s plan to enter the diabetes market with a first-of-its-kind oral non-immunosuppressive therapeutic (TIX100) targeting thioredoxin-interacting protein (TXNIP) for the potential treatment of T1DM, T2DM, and MASH. Recall, in July 2024, TIXiMED announced it obtained IND approval (previous FENIX insight). Below, FENIX provides highlights from our interview with TIXiMED senior leadership, including insight into TIXiMED’s TIX100 MOA and the company’s goal to bring the first oral T1DM therapy to market. 

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.